Passage Bio further expands gene therapy research partnership with Penn
Passage Bio has exercised two additional options for potential new drug candidates under its research collaboration with the University of Pennsylvania's gene therapy program.
The options cover potential gene therapies for Huntingdon's disease, a rare and inherited disease that causes the progressive breakdown of nerve cells in the brain, and Canavan disease, one of the most common degenerative cerebral diseases in infancy.
Financial terms of deal were not disclosed. According to documents filed…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: John George Source Type: news
More News: Brain | Gene Therapy | Genetics | Health Management | Neurology | Partnerships | Pharmaceuticals | University of Pennsylvania